CLCM
PBYI icon

Crawford Lake Capital Management’s Puma Biotechnology PBYI Stock Holding History

Crawford Lake Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,000
Closed -$2.19M – 115
2017
Q2 		$2.19M Buy
+25,000
New +$1.4M 0.48% 63

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Crawford Lake Capital Management's PBYI Position: Q3 2017 in Review

Crawford Lake Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2017, closing a stake of 25,000 shares — an estimated $2.19M sold.

Crawford Lake Capital Management first reported a position in PBYI in Q2 2017 and held it in 1 quarter. The position peaked at $2.19M in Q2 2017. 171 funds tracked by Wall St. Rank hold PBYI as of Q3 2017.

  • Crawford Lake Capital Management reported no remaining Puma Biotechnology position as of Q3 2017 after selling out during the quarter.
  • Crawford Lake Capital Management sold 25,000 Puma Biotechnology shares in Q3 2017, an estimated $2.19M.
  • Crawford Lake Capital Management first reported a position in Puma Biotechnology in Q2 2017 and held it in 1 quarter.
  • Crawford Lake Capital Management's Puma Biotechnology position peaked at $2.19M in Q2 2017.
  • 171 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2017.

Based on Crawford Lake Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.